Methods of using regenerative cells in the treatment of inherited and acquired disorders of the bone, bone marrow, liver, and other tissues

• US 20050048036A1
• Filed: 07/01/2004
• Published: 03/03/2005
• Est. Priority Date: 12/07/2001
• Status: Abandoned Application

• Current Assignee: Lorem Vascular Pte. Ltd.
• Original Assignee: Lorem Vascular Pte. Ltd.
• Inventors: Fraser, John K., Hedrick, Marc H.
• Application Number:
  US10/885,294
• Publication Number:
  US 20050048036A1
• Time in Patent Office: Days
• US Class Current: 424/93.700
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 35/44 Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
• CPC Class Codes: A61L 2300/414 Growth factors
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2430/40 Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
• CPC Class Codes: A61L 27/3834 Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: C12N 5/0667 Adipose-derived stem cells [ADSC]; Adipose stromal stem cells

Abstract

Stem cells, e.g. HSC and MSC-like stem cells, present in adipose tissue are used to treat diseases and disorders that would benefit from a hematopoietic stem cell transplant. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic renal benefit.

Claims

1. A method for treating a disease or disorder of a patient that can benefit from a hematopoietic stem cell (HSC) transplant, comprising administering to the patient a concentration of regenerative cells.

2. The method of claim 1, wherein the disease or disorder is selected from leukemia, lymphoma, breast cancer, multiple myeloma, myelodysplastic syndromes, inherited immunodeficiency, aplastic anemia, thalassemia and sickle cell anemia.

3. The method of claim 1, wherein the regenerative cells are comprised of hematopoietic stem cells (HSC).

4. The method of claim 1, wherein the regenerative cells are comprised of MSC-like stem cells.

5. The method of claim 1, wherein the regenerative cells are comprised of a combination of HSC and MSC-like stem cells.

6. The method of claim 1, wherein the disease or disorder is an autoimmune disease or disorder selected from sclerosis, systemic sclerosis, alopecia universalis, systemic lupus erythematosus, Type I Diabetes, hemolytic anemia, autoimmune cytopenia, autoimmune thrombocytopenia, rheumatoid arthritis and anti-phospholipid syndromes.

7. The method of claim 1, wherein the disease or disorder is a metabolic storage disease or disorder selected from Gaucher'"'"'s Disease, Hurler Syndrome, Hunter Syndrome, Mucopolysaccharidoses, Sanfilippo Disease, beta glucuronidase deficiency, arylsulfatase deficiency, Fabray disease, Krabbe Disease and muscular dystrophy.

8. The method of claim 1, wherein the method comprises administering a bolus of the regenerative cells.

9. The method of claim 1, wherein the method comprises administering multiple doses of the regenerative cells.

10. The method of claim 1, wherein the method further comprises administering one or more hematopoietic growth factors.

11. The method of claim 1, wherein the wherein the method further comprises administering one or more immunosuppressive drugs.

12. The method of claim 1, wherein the regenerative cells are administered via an endocardial administration route.

13. The method of claim 1, wherein the method further comprises administering the regenerative cells to the patient'"'"'s vasculature.

14. The method of claim 1, wherein the regenerative cells are grown in cell culture prior to being administered to the patient.

15. The method of claim 14, wherein the regenerative cells are grown in culture conditions that promote differentiation towards a hematopoietic phenotype.

16. The method of claim 14, wherein the cell culture conditions promote differentiation towards an endothelial phenotype.

17. The method of claim 14, wherein the cell culture is performed on a scaffold material to generate a two or three dimensional construct that can be placed on or within the patient.

18. The method of claim 17, wherein the scaffold material is resorbable in vivo.

19. The method of claim 1, wherein the regenerative cells are modified by gene transfer such that expression of one or more genes in the modified regenerative cells is altered.

20. The method of claim 19, wherein the modification results in alteration of the level of angiogenesis in the subject.

21. The method of claim 19, wherein the modification results in alteration of the level of apoptosis in the subject.

22. The method of claim 1, further comprising controlling the flow of cells in the patient'"'"'s vasculature.

23. The method of claim 22, wherein the flow of cells is controlled by one or more blood occlusion devices located in the patient'"'"'s vasculature.